Barriers to treatment access and informed patient choice in the treatment of opioid dependence in Europe

Heroin Addiction and Related Clinical Problems

Volumn 14, Issue 4, 2012, Pages 65-80

  Benyamina, Amine ^a   Stöver, Heino ^b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b FRANKFURT UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

Access; Barriers; Informed choice; Treatment rules

Indexed keywords

ACCESS TO INFORMATION; ARTICLE; EUROPE; HEALTH CARE ACCESS; HELP SEEKING BEHAVIOR; HUMAN; INFORMATION SEEKING; MAJOR CLINICAL STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT DECISION MAKING; PATIENT EDUCATION; PATIENT INFORMATION; PRIORITY JOURNAL;

EID: 84871630411     PISSN: 15921638     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. BELL J., SHANAHAN M., MUTCH C., REA F., RYAN A., BATEY R., DUNLOP A., WINSTOCK A. (2007): A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 102: 1899-1907.
2. CENTER FOR SUBSTANCE ABUSE TREATMENT. (1999): Enhancing Motivation for Change in Substance Abuse Treatment. Last accessed 21 August 2012 at http://www.ncbi.nlm.nih.gov/books/NBK64967/.
3. CENTER FOR SUBSTANCE ABUSE TREATMENT. (2004): Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Last accessed 8 April 2011 at www.kap.samhsa.gov/products/manuals/index.htm.
4. EMCDDA. (2011): 2011 Annual report on the state of the drugs problem in Europe. Last accessed 30 October 2012 at www.emcdda.europa.eu.
5. EMCDDA. (2011): Data: statistical bulletin 2011. Last accessed 30 October 2012 at www.emcdda.europa.eu.
6. EMCDDA. (2012): Country legal profiles: Sweden. Last accessed 30 July 2012 at www.emcdda.europa.eu.
7. FISCHER G., STÖVER H. (2012): Assessing the current state of opioid-dependence treatment across Europe: methodology of the European Quality Audit of Opioid Treatment (EQUATOR) project. Heroin Addict Relat Clin Probl 14: 5-70.
8. FRISCHKNECHT U., BECKMANN B., HEINRICH M., KNIEST A., NAKOVICS H., KIEFER F., MANN K., HERMANN D. (2011): The vicious circle of perceived stigmatization, depressiveness, anxiety, and low quality of life in substituted heroin addicts. Eur Addict Res 17: 241-249.
9. MCLELLAN A.T., LEWIS D.C., O'BRIEN C.P., KLEBER H.D. (2000): Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284: 1689-1695.
10. MICHELS I.I., STOVER H., GERLACH R. (2007): Substitution treatment for opioid addicts in Germany. Harm Reduct J 4: 5.
11. NATIONAL BOARD OF HEALTH DENMARK. (2008): Guidance No. 42 on Medical Treatment of Drug Abusers in Substitution Treatment for Opioid Dependence. Last accessed 18 June 2012 at www.sst.dk.
12. ORMAN J.S., KEATING G.M. (2009): Buprenorphine/ naloxone: a review of its use in the treatment of opioid dependence. Drugs 69: 577-607.
13. PINTO H., MASKREY V., SWIFT L., RUMBALL D., WAGLE A., HOLLAND R. (2010): The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat 39: 340-352.
14. SOYKA M., ZINGG C., KOLLER G., KUEFNER H. (2008): Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol 11: 641-653.
15. STÖVER H. (2011): Barriers to Opioid Substitution Treatment Access, Entry and Retention: A Survey of Opioid Users, Patients in Treatment, and Treating and Non-Treating Physicians. Eur Addict Res 17: 44-54.
16. WEIDEN P., GLAZER W. (1997): Assessment and treatment selection for "revolving door" inpatients with schizophrenia. Psychiatr Q 68: 377-392.
17. WORLD HEALTH ORGANIZATION. (2009): Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Last accessed 26 October 2012 at www.who.int.